30
Participants
Start Date
October 31, 2025
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2029
Pembrolizumab & Enfortumab Vedotin (PEV)
Patients in the study will receive 1L PEV with 1.25 mg/kg of EV on day 1 and day 8 every 21 days, and 200 mg of pembrolizumab every 21 days.
Pembrolizumab
Patients will receive 400 mg of pembrolizumab every 42 days. During the de-escalation period from PEV.
Pembrolizumab & Enfortumab Vedotin (PEV)
If patients experience radiographic progression on pembrolizumab monotherapy, they will undergo rechallenge with PEV.
OU Health Stephenson Cancer Center, Oklahoma City
Collaborators (1)
Natera, Inc.
INDUSTRY
University of Oklahoma
OTHER